|
1) Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004; 127: S232-41
|
|
|
|
2) Palmer DH, Hussain SA, Johnson PJ. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2005; 5: 507-23
|
|
|
|
|
3) Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006; 25: 3866-84
|
|
|
|
|
|
4) Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001; 134: 963-7
|
|
|
|
|
|
5) Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 31: 54-8
|
|
|
|
|
|
6) Urabe T, Kaneko S, Matsushita E, et al. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology. 1998; 55: 39-47
|
|
|
|
|
|
7) Yin X, Lu M, Liang L, et al. Systemic chemo-immunotherapy for advance-stage hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 2526-9
|
|
|
|
|
|
8) Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/ interferonα-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 1532-8
|
|
|
|
|
|
9) Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002; 94: 435-42
|
|
|
|
|
|
10) Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer. 2005; 93: 557-64
|
|
|
|
|
|
11) Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990-7
|
|
|
|
|
|
12) Takehara T, Uemura A, Tatsumi T, et al. Natural killer cell-mediated ablation of metastatic liver tumors by hydrodynamic injection of IFNα gene to mice. Int J Cancer. 2007; 120: 1252-60
|
|
|
|
|
|
13) Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316: 889-97
|
|
|
|
|
|
14) Matsuda H, Takehara T, Naito M, et al. Adoptive immunotherapy for the treatment of patients with hepatocellular carcinoma. Acta Hepatologica Japonica. 1990; 31: 428-34
|
|
|
|
|
|
15) Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356: 802-7
|
|
|
|
|
|
16) Takeda T, Watanabe M, Umeshita K, et al. Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy. Jpn J Cancer Chemother. 2004; 31: 1646-8
|
|
|
|
|
|
17) Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterology, 2004; 10: 1146-51
|
|
|
|
|
|
18) Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002; 17: 889-96
|
|
|
|
|
|
19) Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003; 52: 155-61
|
|
|
|
|
|
20) Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 2003; 21: 135-42
|
|
|
|
|
|
21) Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005; 28: 496-505
|
|
|
|
|
|
22) Nakamoto Y, Mizukoshi E, Tsuji H, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol. 2007; 147: 296-305
|
|
|
|
|
|
23) Mizukoshi E, Nakamoto Y, Tsuji H, et al. Identifi-cation ofα-fetoprotein-derived peptides recog-nized by cytotoxic T lymphocytes in HLA-A24＋ patients with hepatocellular carcinoma. Int J Cancer. 2006; 118: 1194-204
|
|
|
|
|
|
24) Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8＋ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005; 174: 1709-16
|
|
|
|
|
|
25) Shang XY, Chen HS, Zhang HG, et al. The spontaneous CD8＋ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res. 2004; 10: 6946-55
|
|
|
|
|
|
26) Zhang HG, Chen HS, Peng JR, et al. Specific CD8(＋) T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother. 2007. (Epub, in press)
|
|
|
|
|
|
27) Komori H, Nakatsura T, Senju S, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 2689-97
|
|
|
|
|
|
28) Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A＊0201 immunodominant peptides derived fromα-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003; 9: 5902-8
|
|
|
|
|
|
29) Butterfield LH, Ribas A, Dissette VB, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with fourα-fetoprotein peptides. Clin Cancer Res. 2006; 12: 2817-25
|
|
|
|
|
|
30) Mizukoshi E, Nakamoto Y, Marukawa Y, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology. 2006; 43: 1284-94
|
|
|
|
|
|
31) Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor specific T-cell responses. Cancer Res. 2006; 66: 1139-46
|
|
|
|
|
|
32) Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev. 2000; 174: 5-20
|
|
|
|
|
|
33) Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery ofα-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology. 2007; 45: 22-30
|
|
|
|
|